Mouse CD31/PECAM-1 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Mouse CD31/PECAM-1 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Mouse CD31/PECAM-1 |
| Clone | [390] |
| Host Species | Rat |
| Reactive Species | mouse |
| Isotype | IgG2a kappa |
| Format | unconjugated |
| Size | 0.5 mg |
| Concentration | n/a |
| Applications | Flow Cytometry; Immunohistochemistry (Frozen Sections); Immunoprecipitation |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Mouse CD31/PECAM-1, Mr 130-140 kDa. CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), is a type I integral membrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is constitutively expressed on the surface of endothelial cells, and concentrated at the junction between them. It is also weakly expressed on many peripheral lymphoid cells and paltelets.^1-3 CD31 interacts homotypically in cell adhesion assays. MAb 390 inhibits the aggregation of L cells transfected with a variant form of CD31.^1, 3. |
| Immunogen | Immunogen: Mouse leukocyte cell line 32D |
| Other Names | n/a |
| Gene, Accession # | n/a |
| Catalog # | MBS673319 |
| Price | $260 |
| Order / More Info | Mouse CD31/PECAM-1 Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Abelda, S.M. Personal communication2. Buck, C.A., H.S. Baldwin, H. DeLisser, C. Mickanin, H.-M. Shen, G. Kennedy, A. Chen, J.M. Edelman, and S.M. Abelda. 1993. Comptes Rendus de l-Academie des Sciences Serie III-Sciences de la Vie-Life Sciences 316:838.3. DeLisser, H.M., P.J. newman, and S.M. Abelda. 1993. Curr. Topics Microbiol. Immunol. 184:37. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies